Literature DB >> 20865466

Cevimeline (Evoxac ®) overdose.

Berenika Voskoboynik1, Kavita Babu, Jason B Hack.   

Abstract

Cevimeline (Evoxac ®) is an oral muscarinic agent that has been recently approved for the treatment of xerostomia in the setting of Sjogren's syndrome. Its toxicity in overdose has not been reported in the medical literature to date. We report a previously healthy patient who intentionally ingested approximately 10 mg/kg of cevimeline and presented with symptoms of muscarinic excess and mental status depression. The patient recovered uneventfully after receiving activated charcoal and supportive care. This report describes the first documented cevimeline overdose. © American College of Medical Toxicology 2010

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20865466      PMCID: PMC3614114          DOI: 10.1007/s13181-010-0112-8

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  7 in total

1.  Pilocarpine toxicity and the treatment of xerostomia.

Authors:  Robert G Hendrickson; Anthony P Morocco; Michael I Greenberg
Journal:  J Emerg Med       Date:  2004-05       Impact factor: 1.484

2.  Organophosphate poisoning: grading the severity and comparing treatment between atropine and glycopyrrolate.

Authors:  P G Bardin; S F Van Eeden
Journal:  Crit Care Med       Date:  1990-09       Impact factor: 7.598

3.  Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial.

Authors:  Rose S Fife; Walter F Chase; Robin K Dore; Craig W Wiesenhutter; Peter B Lockhart; Elizabeth Tindall; James Y Suen
Journal:  Arch Intern Med       Date:  2002-06-10

4.  A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.

Authors:  Dianne Petrone; John J Condemi; Rose Fife; Oscar Gluck; Stanley Cohen; Paul Dalgin
Journal:  Arthritis Rheum       Date:  2002-03

5.  General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.

Authors:  Hirohiko Arisawa; Eiichi Imai; Nobuaki Fujise; Kenji Fukui; Hiroaki Masunaga
Journal:  Arzneimittelforschung       Date:  2002

6.  Cevimeline.

Authors:  Juliane Weber; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Management of acute organophosphorus pesticide poisoning.

Authors:  Michael Eddleston; Nick A Buckley; Peter Eyer; Andrew H Dawson
Journal:  Lancet       Date:  2008-02-16       Impact factor: 79.321

  7 in total
  3 in total

Review 1.  Artificial Saliva for Therapeutic Management of Xerostomia: A Narrative Review.

Authors:  Hajer Ayed Alhejoury; Lina Fouad Mogharbel; Mohammed Ahmed Al-Qadhi; Suzan Sulaiman Shamlan; Amal Fuad Alturki; Wafaa Mohammed Babatin; Renad Abdualrahman Mohammed Alaishan; Fawaz Pullishery
Journal:  J Pharm Bioallied Sci       Date:  2021-11-10

2.  Clemastine Promotes Differentiation of Oligodendrocyte Progenitor Cells Through the Activation of ERK1/2 via Muscarinic Receptors After Spinal Cord Injury.

Authors:  Lu-Yao Tong; Yong-Bing Deng; Wei-Hong Du; Wen-Zhu Zhou; Xin-Yu Liao; Xue Jiang
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

3.  Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report.

Authors:  Blake Acquarulo; Priya Tandon; Carolyn M Macica
Journal:  J Med Case Rep       Date:  2022-06-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.